After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
The usually conservative group spends big on Dicerna – but others might be interested too.
Gilead opts in at long last, and that’s more than many might have been expecting.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.